Oruka Says Experimental Annual Psoriasis Treatment Clears Skin in ...

Oruka says experimental annual psoriasis treatment clears skin in ...

Oruka surges as long-acting psoriasis drug shows early promise

A therapy that works similarly to AbbVie’s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the potential to be dosed less frequently.

Oruka’s long-acting psoriasis therapy posts strong results in mid-stage study

The drug could become a new treatment option for patients, and a blockbuster, if data hold up in late-stage trials.

Oruka reports positive data from Phase IIa trial for plaque psoriasis

Oruka Therapeutics has reported positive interim data from the ongoing EVERLAST-A Phase IIa trial evaluating ORKA-001 in patients with moderate-to-severe plaque psoriasis.The post Oruka reports positive data from Phase IIa trial for plaque psoriasis appeared first on Clinical Trials Arena.

Oruka posts Phase 2 win in psoriasis, hoping to compete with Skyrizi

Oruka Therapeutics' Phase 2 psoriasis data could mean there's a future challenger to megablockbuster Skyrizi. The company said on Monday that 40 of 63 patients (63.5%) who took an experimental drug saw their skin plaques ...